Box 2
Contains 32 Results:
Iridium 191m for Pediatric Cardiac Imaging: grant application, 1980
Consists of documentation relating to studies in 51Cr-EDTA, Copper 62 Radiopharmeceuticals, Iridium-191m, Osmium-191, Positron Emission Tomography (PET), and Single-Photon Emission Computed Tomography (SPECT). This is concerned mainly with funding acquisition, protocol development, and reporting to funders, though some of the material relates to human study patient consent, and reporting on study results
Iridium 191m Generator: patent application, correspondence, 1983
Consists of documentation relating to studies in 51Cr-EDTA, Copper 62 Radiopharmeceuticals, Iridium-191m, Osmium-191, Positron Emission Tomography (PET), and Single-Photon Emission Computed Tomography (SPECT). This is concerned mainly with funding acquisition, protocol development, and reporting to funders, though some of the material relates to human study patient consent, and reporting on study results
Iridium 191m: notice of claimed investigational exemption for a new drug, 1981
Consists of documentation relating to studies in 51Cr-EDTA, Copper 62 Radiopharmeceuticals, Iridium-191m, Osmium-191, Positron Emission Tomography (PET), and Single-Photon Emission Computed Tomography (SPECT). This is concerned mainly with funding acquisition, protocol development, and reporting to funders, though some of the material relates to human study patient consent, and reporting on study results
Iridium 191m: statement of investigator, Robert Roberts, MD, 1985
Consists of documentation relating to studies in 51Cr-EDTA, Copper 62 Radiopharmeceuticals, Iridium-191m, Osmium-191, Positron Emission Tomography (PET), and Single-Photon Emission Computed Tomography (SPECT). This is concerned mainly with funding acquisition, protocol development, and reporting to funders, though some of the material relates to human study patient consent, and reporting on study results
Iridium 191m: notice of claimed investigational exemption for a new drug, 1987
Consists of documentation relating to studies in 51Cr-EDTA, Copper 62 Radiopharmeceuticals, Iridium-191m, Osmium-191, Positron Emission Tomography (PET), and Single-Photon Emission Computed Tomography (SPECT). This is concerned mainly with funding acquisition, protocol development, and reporting to funders, though some of the material relates to human study patient consent, and reporting on study results
Natural Osmium 191-Ir 191m Generator for Cardiac Imaging: grant application, 1982
Consists of documentation relating to studies in 51Cr-EDTA, Copper 62 Radiopharmeceuticals, Iridium-191m, Osmium-191, Positron Emission Tomography (PET), and Single-Photon Emission Computed Tomography (SPECT). This is concerned mainly with funding acquisition, protocol development, and reporting to funders, though some of the material relates to human study patient consent, and reporting on study results
Normal Hepatic and Splenic Sizes in Children: correspondence, data, drafts, figures, 1986
Consists of documentation relating to studies in 51Cr-EDTA, Copper 62 Radiopharmeceuticals, Iridium-191m, Osmium-191, Positron Emission Tomography (PET), and Single-Photon Emission Computed Tomography (SPECT). This is concerned mainly with funding acquisition, protocol development, and reporting to funders, though some of the material relates to human study patient consent, and reporting on study results
Observations of the Determination of Toxicity of Eluate of the 191OS-191IR Generator - Oxalate Type: data, notes, 1984
Consists of documentation relating to studies in 51Cr-EDTA, Copper 62 Radiopharmeceuticals, Iridium-191m, Osmium-191, Positron Emission Tomography (PET), and Single-Photon Emission Computed Tomography (SPECT). This is concerned mainly with funding acquisition, protocol development, and reporting to funders, though some of the material relates to human study patient consent, and reporting on study results
Osmium 191 / Iridium 191m Radionuclide Generator: correspondence, proposals, 1983-1990
Consists of documentation relating to studies in 51Cr-EDTA, Copper 62 Radiopharmeceuticals, Iridium-191m, Osmium-191, Positron Emission Tomography (PET), and Single-Photon Emission Computed Tomography (SPECT). This is concerned mainly with funding acquisition, protocol development, and reporting to funders, though some of the material relates to human study patient consent, and reporting on study results
Osmium 191 / Iridium 191m Studies: correspondence, reports, 1983-1985
Consists of documentation relating to studies in 51Cr-EDTA, Copper 62 Radiopharmeceuticals, Iridium-191m, Osmium-191, Positron Emission Tomography (PET), and Single-Photon Emission Computed Tomography (SPECT). This is concerned mainly with funding acquisition, protocol development, and reporting to funders, though some of the material relates to human study patient consent, and reporting on study results